Scarica l'app Stockscreener
16.61
0.78%
-0.13
Dopo l'orario di chiusura:
16.62
0.01
+0.06%
Precedente Chiudi:
$16.74
Aprire:
$16.86
Volume 24 ore:
211.09K
Relative Volume:
0.45
Capitalizzazione di mercato:
$738.36M
Reddito:
$9.00M
Utile/perdita netta:
$-80.61M
Rapporto P/E:
-7.4046
EPS:
-2.2432
Flusso di cassa netto:
$-82.35M
1 W Prestazione:
-5.95%
1M Prestazione:
-9.53%
6M Prestazione:
+92.02%
1 anno Prestazione:
+311.14%
Intervallo 1D:
$16.60
$17.33
Intervallo di 1 settimana:
$14.72
$18.25
Portata 52W:
$3.79
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Nome
Bioage Labs Inc
Settore
Telefono
510-806-1445
Indirizzo
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
16.61 | 744.14M | 9.00M | -80.61M | -82.35M | -2.2432 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Needham | Buy |
| 2026-02-25 | Iniziato | Oppenheimer | Outperform |
| 2026-02-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2026-01-27 | Iniziato | Piper Sandler | Overweight |
| 2025-12-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2024-12-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-21 | Iniziato | Citigroup | Buy |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-21 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioage Labs Inc Borsa (BIOA) Ultime notizie
BIOA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioAge executives to speak at Jefferies and Goldman healthcare forums - Stock Titan
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - Insider Monkey
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
Shareholders that lost money on BioAge Labs, Inc.(BIOA) should c - GuruFocus
Khosla affiliates hold 1.8M shares in BioAge Labs (NASDAQ: BIOA), 4.0% stake - Stock Titan
BioAge Labs, Inc.Common Stock (NQ: BIOA - FinancialContent
Cormorant Asset Management reports 6.51% stake in BioAge Labs (BIOA) - Stock Titan
BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week - Traders Union
Number of shareholders of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
BioAge Labs : BIOA - 24/7 Wall St.
Inside the cell-based Klotho therapy aiming to restore a longevity protein - Stock Titan
BTIG initiates coverage of BioAge Labs (BIOA) with buy recommendation - MSN
BTIG Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40 - Moomoo
BioAge Labs, Inc (BIOA) Stock News & Articles - 24/7 Wall St.
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - Yahoo Finance
BTIG Initiates BioAge Labs at Buy With $40 Price Target - marketscreener.com
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
TradingKey - TradingKey
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge Labs Releases Q1 2026 Financial Results - AlphaStreet
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials - Barchart.com
BioAge Labs 1Q Research and Development Expenses Approximately $20.4M >BIOA - Moomoo
BioAge Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioAge Labs 1Q Loss/Shr 52c >BIOA - Moomoo
BioAge Labs Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
BioAge Labs Reports Positive Phase 1 Results for BGE-102 and Plans Upcoming Clinical Trials in Cardiovascular Risk and Diabetic Macular Edema - Quiver Quantitative
Earnings Flash (BIOA) BioAge Labs, Inc. Reports Q1 Collaboration Revenue $2.8M, vs. FactSet Est of $1.1M - marketscreener.com
BioAge Labs (NASDAQ: BIOA) Q1 2026 loss deepens amid R&D and pipeline push - Stock Titan
[10-Q] BioAge Labs, Inc. Quarterly Earnings Report - Stock Titan
BioAge lines up 2 mid-2026 trials for once-daily pill after $132M raise - Stock Titan
Earnings Flash (BIOA) BioAge Labs, Inc. Reports Q1 Collaboration Revenue $2.8M, Vs. FactSet Est of $1.1M - Moomoo
Press Release: BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
BioAge to preview early data for heart and retinal disease drug - Stock Titan
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - The Manila Times
PRN_FinancialWrapper | PR NewswireBioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - FinancialContent
BlackRock (NYSE: BIOA) reports 2.24M shares of BioAge; 5.03% stake - Stock Titan
BioAge Labs (NASDAQ:BIOA) Trading 8.6% HigherHere's Why - MarketBeat
BioAge Labs plans up to $75M public stock offering; shares down - MSN
Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell - MarketBeat
BioAge Labs (BIOA) CFO exercises 3,542 options, now holds 36,575 shares - Stock Titan
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile - MarketBeat
BIOA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class ActionBIOA - TMX Newsfile
BIOA SEC FilingsBioAge Labs Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1%Time to Sell? - MarketBeat
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans - Sahm
BIOA (BioAge Labs Inc.) Q4 2025 loss narrows more than expected, shares climb 8.83 percent on investor enthusiasm. - Xã Vĩnh Công
[ARS] BioAge Labs, Inc. SEC Filing - Stock Titan
Jefferies reiterates BioAge Labs stock rating on dose data By Investing.com - Investing.com South Africa
Bioage Labs Inc Azioni (BIOA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.92%
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):